Ad
related to: ocular amyloidosis treatment mayo clinic- Diagnosing ATTR
Get familiar with the tests
Know how you can help your doctor
- Reveal More About ATTR
There's more to uncover with ATTR
Learn how ATTR can worsen over time
- Living With ATTR
Learn how ATTR affects daily life
Know how ATTR affects your health
- Sign Up
Get updates about ATTR
Complete the form to get more info
- Diagnosing ATTR
Search results
Results from the WOW.Com Content Network
Treatment depends on the type of amyloidosis that is present. Treatment with high dose melphalan, a chemotherapy agent, followed by stem cell transplantation has shown promise in early studies and is recommended for stage I and II AL amyloidosis. [26] However, only 20–25% of people are eligible for stem cell transplant.
AL amyloidosis is caused by the deposition of abnormal antibody free light chains. The abnormal light chains are produced by monoclonal plasma cells, and, although AL amyloidosis can occur without diagnosis of another disorder, it is often associated with other plasma cell disorders, such as multiple myeloma and Waldenström's macroglobulinemia. [6]
LECT2 Amyloidosis (ALECT2) is a form of amyloidosis caused by the LECT2 protein. It was found to be the third most common (~3% of total) cause of amyloidosis in a set of more than 4,000 individuals studied at the Mayo Clinic; the first and second most common forms the disorder were AL amyloidosis and AA amyloidosis, respectively.
Pseudoexfoliation syndrome, often abbreviated as PEX [1] and sometimes as PES or PXS, is an aging-related systemic disease manifesting itself primarily in the eyes which is characterized by the accumulation of microscopic granular amyloid-like protein fibers. [2]
Treatments aimed at symptom relief are available, and include diuretics, pacemakers, and arrhythmia management. Thus, Senile systemic amyloidosis and familial amyloid polyneuropathy are often treatable diseases that are misdiagnosed. [9] [10] [11]
As reported by Dispenzieri et al. [4] Mayo Clinic treatment regimens are tailored to treat the clinical manifestations and prognosis for the rate of progression of the POEMS syndrome in each patient. In rare cases, patients may have minimal or no symptoms at presentation or after successful treatment of their disorder.
Robert A. Kyle is a professor of medicine, Laboratory Medicine and Pathology at the Mayo Clinic.He specializes in the care of patients with plasma cell dyscrasias. . Throughout his career Kyle has published more than 1,850 scientific papers and abstracts on myeloma and other plasma cell diso
AA amyloidosis is a form of amyloidosis, a disease characterized by the abnormal deposition of fibers of insoluble protein in the extracellular space of various tissues and organs. In AA amyloidosis, the deposited protein is serum amyloid A protein (SAA), an acute-phase protein which is normally soluble and whose plasma concentration is highest ...
Ad
related to: ocular amyloidosis treatment mayo clinic